📈 Jumpstart Signal Watchlist — November 05, 2026

🏢 What they do: DiamondRock Hospitality Company (DRH) is a self-advised real estate investment trust (REIT) that owns a portfolio of approximately 35-36 premium hotels and resorts with about 9,600 rooms, concentrated in U.S. gateway markets and leisure destinations.
- 🎯 Current $13.98 is 4% below 3yr high $14.63 · ⏳ SMA200 $11.38 (current price $13.98 is above) · 💰 Market Cap $2.9B
- DRH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 52/60
- 🏦 Low drawdown (10.5% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 60% (>20%); Low LT D/E 0.71 (<1.0); PEG ratio 0.29 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ What DiamondRock Hospitality (DRH) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 DiamondRock reported stronger third-quarter operating performance, including 6.6% comparable RevPAR growth and a 12.5% increase in Hotel Adjusted EBITDA. It also raised its 2026 outlook, supporting a positive view of its earnings and cash-flow prospects.
✅ DiamondRock Hospitality Company Q3 2026 Earnings Call Summary — Yahoo Finance.
🤖 The call summary highlights broad-based demand, margin expansion, and a 175-basis-point increase to the midpoint of 2026 RevPAR guidance. Expected savings from a renegotiated franchise agreement and the Bellmoor acquisition add potential support.
⚪️ DiamondRock Hospitality (DRH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates — Yahoo Finance.
🤖 Revenue grew year over year, but slightly missed consensus, while diluted EPS was below the cited analyst estimate. FFO met expectations, leaving a mixed results picture.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Apple Hospitality REIT is a real estate investment trust that owns upscale, rooms-focused hotels across the United States. Most of its properties operate under Hilton, Marriott, or Hyatt brands.
- 🎯 Current $18.15 is 4% below 3yr high $18.83 · ⏳ SMA200 $14.73 (current price $18.15 is above) · 💰 Market Cap $4.3B
- APLE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 Low drawdown (10.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 24% (>20%); Low LT D/E 0.47 (<1.0); PEG ratio 0.96 (<1.5).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (59) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×1; showing 3 of 4).
✅ Apple Hospitality REIT Reports Results of Operations for Third Quarter 2026 — Business Wire.
🤖 Third-quarter operating results improved year over year, including adjusted hotel EBITDA up 14.7% and MFFO up 16.0%. Preliminary October comparable-hotel RevPAR growth of approximately 10% and raised 2026 guidance also point to stronger performance.
✅ Apple Hospitality REIT (APLE) Q3 FFO and Revenues Surpass Estimates — Yahoo Finance.
🤖 Adjusted FFO of $0.50 per share beat the $0.47 consensus estimate, while revenue of $398.33 million exceeded estimates by 1.2%. Both measures also increased from the year-ago quarter.
⚪️ Apple Hospitality REIT Announces Monthly Distribution — Business Wire.
🤖 The company declared its regular monthly cash distribution of $0.08 per share. This maintains the existing payout rather than announcing a change in the distribution.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: ACCO Brands designs, manufactures, and markets branded office, school, and consumer products. Its offerings include notebooks and planners, filing and organization supplies, office equipment, computer accessories, and gaming products.
- 🎯 Current $5.26 is 20% below 3yr high $6.59 · ⏳ SMA200 $3.99 (current price $5.26 is above) · 💰 Market Cap $485M
- ACCO shows decent technicals supported by positive sentiment.

💎 Quality (Q): 44/60
- 🏦 Low drawdown (11.9% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 200% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (9.5%)
- 🔔 Strong above EMA50 (15.6%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ Wall Street Zen Upgrades Acco Brands (NYSE:ACCO) to Strong-Buy — MarketBeat.
🤖 Wall Street Zen upgraded ACCO from Buy to Strong Buy. The article also notes that Q3 adjusted EPS beat consensus, although revenue was below estimates.
✅ ACCO Brands Corporation Q3 2026 Earnings Call Summary — Yahoo Finance.
🤖 The summary highlights improved adjusted gross profit and margins, tariff refunds, and the Trust acquisition, which expands ACCO’s technology peripherals platform. Comparable sales declined, tempering the positive picture.
❌ Q4 EPS Estimates for Acco Brands Lowered by Noble Financial — MarketBeat.
🤖 Noble Financial lowered its Q4 2026 EPS estimate from $0.40 to $0.38, a modestly negative revision. The article also mentions rating upgrades from other firms, but the estimate cut is the specific new development.
🍭 Bonus (B): 0/10 — Printing & Publishing

🏢 What they do: Aveanna Healthcare provides in-home nursing and therapy, home health and hospice care, and medical supplies such as enteral nutrition products. Its services support children and adults with complex medical needs.
- 🎯 Current $13.67 is 5% below 3yr high $14.38 · ⏳ SMA200 $9.38 (current price $13.67 is above) · 💰 Market Cap $3.0B
- AVAH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 Base breakout (range: 9.9%); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 38% (>20%); ROE 96% (>15%); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×1).
✅ Is Aveanna Healthcare Holdings (AVAH) Still Below Fair Value Following Its Zacks Upgrade? — Yahoo Finance.
🤖 The article reports a Zacks Rank of #2 and an approximately 14.1% increase in full-year earnings estimates over the prior three months. It also cites a fair-value estimate above the recent share price, suggesting potential upside.
✅ Raymond James adds Humana and Avahlth to healthcare list — Investing.com.
🤖 Raymond James added Aveanna to its monthly healthcare selections, citing continued momentum and potential benefits from a California rate increase in 2027. This is a favorable analyst view, though the cited rate increase is prospective.
⚪️ Aveanna Healthcare (AVAH) Stock Looks Reasonable On Its Huge 3 Year Run — Yahoo Finance.
🤖 The article discusses Aveanna’s strong three-year share-price performance and valuation, noting that its earnings power will need to support investor expectations. It presents a valuation discussion rather than a new company-specific catalyst.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $68.71 is 6% below 3yr high $72.75 · ⏳ SMA200 $51.31 (current price $68.71 is above) · 💰 Market Cap $16.8B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 48% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (11.3%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Exelixis (NASDAQ:EXEL) Hits New 1-Year High on Analyst Upgrade — MarketBeat.
🤖 HC Wainwright raised its price target to $78 and maintained a Buy rating. The article also notes that Exelixis beat quarterly earnings and revenue expectations.
✅ Earnings Beat Could Be A Game Changer For Exelixis Stock (EXEL) — Yahoo Finance.
🤖 Exelixis reported third-quarter revenue of $658.7 million and earnings above expectations, while maintaining its full-year revenue guidance. The results indicate continued business growth.
⚪️ Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November — Business Wire.
🤖 The article announces management appearances at upcoming investor conferences but reports no new financial results, guidance, or other company catalyst.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: DocuSign provides electronic signature software and a cloud-based platform for managing agreements. Its services help organizations create, route, sign, automate, and analyze contracts and other documents.
- 🎯 Current $78.92 is 26% below 3yr high $106.99 · ⏳ SMA200 $55.33 (current price $78.92 is above) · 💰 Market Cap $14.9B
- DOCU shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 33% (>20%); ROE 19% (>15%); Low LT D/E 0.00 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
- ⚠️ RSI reversing from overbought (54) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ GC AI and Docusign Partner to Turn Agreements into Legal Intelligence — Business Wire.
🤖 The partnership integrates Docusign agreements with GC AI’s contract intelligence platform, enabling legal teams to analyze contracts and retrieve insights faster. This may strengthen the usefulness and reach of Docusign’s agreement-management offerings.
✅ Docusign Named a Leader in the 2026-2027 IDC MarketScape for Worldwide Contract Life-Cycle Management Software for Corporate Legal — Yahoo Finance.
🤖 Docusign announced that IDC named it a Leader in its corporate legal contract life-cycle management software assessment. The recognition may support the company’s credibility and competitive position in the market.
✅ Docusign Acquires Suplari to Accelerate AI-Powered Contract Management for Procurement — Yahoo Finance.
🤖 Docusign acquired AI-native procurement intelligence company Suplari to expand its Intelligent Agreement Management platform. The deal could broaden its procurement capabilities and help customers manage costs, risks, and supplier obligations.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: OneSpan provides cybersecurity and digital agreement solutions, including identity verification, authentication, fraud prevention, and mobile app security. Its digital agreement products support secure e-signatures, online notarization, and automated document workflows.
- 🎯 Current $21.90 is 15% below 3yr high $25.66 · ⏳ SMA200 $14.28 (current price $21.90 is above) · 💰 Market Cap $806M
- OSPN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 Low drawdown (14.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; ROE 25% (>15%); Low LT D/E 0.00 (<1.0); PEG ratio 0.69 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (5.1%)
- 🔔 Strong above EMA50 (15.5%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ OneSpan Reports Third Quarter 2026 Financial Results — Yahoo Finance.
🤖 OneSpan reported third-quarter results and raised its full-year outlook, supported by growth in revenue and subscription sales. The company also described progress on its DigipassONE authentication products.
✅ What Onespan (OSPN) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 The article reports 12% third-quarter revenue growth and raised 2026 revenue, ARR, and adjusted EBITDA outlooks. Those results and improved guidance are positive signals for the stock.
❌ OneSpan Beats Again, But Positives Have Been Priced In (Rating Downgrade) — Seeking Alpha.
🤖 The article acknowledges strong subscription growth and earnings performance but argues that the stock’s gains have priced in much of the good news and that growth expectations are muted. Its valuation concerns and rating downgrade are negative signals.
🍭 Bonus (B): 10/10 — Computer Integrated Systems Design (Technology sector)

🏢 What they do: AtriCure develops and sells surgical medical devices and therapies for treating atrial fibrillation, including cardiac ablation systems and devices to manage the left atrial appendage. It also makes cryoablation probes used to help manage pain after surgery.
- 🎯 Current $61.28 is 6% below 3yr high $65.53 · ⏳ SMA200 $38.70 (current price $61.28 is above) · 💰 Market Cap $3.1B
- ATRC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 900% (>20%); Revenue growth 15% (>15%); Low LT D/E 0.11 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (10.3%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (56) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ What AtriCure (ATRC) Said on Its Q3 Earnings Call — Yahoo Finance.
🤖 AtriCure raised its 2026 revenue outlook to approximately $606 million–$610 million and increased its adjusted EBITDA guidance. The higher outlook is a positive signal about expected business performance.
✅ AtriCure (ATRC) Q3 2026 Earnings Call Transcript — Yahoo Finance.
🤖 AtriCure reported third-quarter revenue of $154.5 million, up 15% year over year, and raised its full-year revenue outlook. The results and improved guidance are positive for the stock.
✅ AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results - AtriCure (NASDAQ:ATRC) — Benzinga.
🤖 AtriCure beat analyst estimates for quarterly earnings and sales and raised its 2026 guidance. BTIG and Needham maintained Buy ratings and raised their price targets to $70.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $76.33 is 14% below 3yr high $88.47 · ⏳ SMA200 $34.89 (current price $76.33 is above) · 💰 Market Cap $4.0B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1067% (>20%); Revenue growth 39% (>15%); ROE 28% (>15%).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (18.9%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×4 ❌×1; showing 3 of 5).
✅ CareDx Announces Third KOAR Analysis Published in Transplantation — Yahoo Finance.
🤖 A new analysis from CareDx’s kidney transplant registry found that early AlloSure Kidney test results were associated with three-year graft outcomes. The publication adds clinical evidence supporting the company’s transplant testing products.
✅ CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth — Yahoo Finance.
🤖 CareDx raised its 2026 revenue and adjusted EBITDA outlook after reporting strong transplant testing demand and improved collections. The article also notes revenue above consensus and plans for an AlloHeme launch in 2027.
❌ CareDx (NASDAQ:CDNA) Rating Lowered to "Buy" at Wall Street Zen — MarketBeat.
🤖 Wall Street Zen lowered its rating from “strong buy” to “buy,” a modestly negative analyst signal. The article also reports that CareDx’s quarterly EPS and revenue exceeded estimates.
🍭 Bonus (B): 0/10 — Medical Laboratories